Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Alan R. Friedman is active.

Publication


Featured researches published by Alan R. Friedman.


Parasitology | 1996

FMRFamide-related peptides (FaRPs) in nematodes : occurrence and neuromuscular physiology

Aaron G. Maule; Jerry W. Bowman; David P. Thompson; Nicola Marks; Alan R. Friedman; Timothy G. Geary

The occurrence of classical neurotransmitter molecules and numerous peptidic messenger molecules in nematode nervous systems indicate that although structurally simple, nematode nervous systems are chemically complex. Thus far, studies on one nematode neuropeptide family, namely the FMRFamide-related peptides (FaRPs), have revealed an unexpected variety of neuropeptide structures in both free-living and parasitic species. To date 23 nematode FaRPs have been structurally characterized including 12 from Ascaris suum, 8 from Caenorhabditis elegans, 5 from Panagrellus redivivus and 1 from Haemonchus contortus. Ten FaRP-encoding genes have been identified in Caenorhabditis elegans. However, the full complement of nematode neuronal messengers has yet to be described and unidentified nematode FaRPs await detection. Preliminary characterization of the actions of nematode neuropeptides on the somatic musculature and neurones of A, suum has revealed that these peptidic messengers have potent and complex effects. Identified complexities include the biphasic effects of KNEFIRFamide/KHEYLRFamide (AF1/2; relaxation of tone followed by oscillatory contractile activity) and KPNFIRFamide (PF4; rapid relaxation of tone followed by an increase in tone), the diverse actions of KSAYMRFamide (AF8 or PF3; relaxes dorsal muscles and contracts ventral muscles) and the apparent coupling of the relaxatory effects of SDPNFLRFamide/SADPNFLRFamide (PF1/PF2) to nitric oxide release. Indeed, all of the nematode FaRPs which have been tested on somatic muscle strips of A. suum have actions which are clearly physiologically distinguishable. Although we are a very long way from understanding how the actions of these peptides are co-ordinated, not only with those of each other but also with those of the classical transmitter molecules, to control nematode behaviour, their abundance coupled with their diversity of structure and function indicates a hitherto unidentified sophistication to nematode neuromuscular intergration.


International Journal for Parasitology | 1995

The pharmacology of FMRFamide-related neuropeptides in nematodes: New opportunities for rational anthelmintic discovery?

Timothy G. Geary; J.W. Bowman; Alan R. Friedman; A.G. Maule; J.P. Davis; C.A. Winterrowd; Ronald D. Klein; David P. Thompson

The chemotherapeutic control of helminth parasites is compromised by the limited number of classes of anthelmintic drugs. Discovery of novel anthelmintics is impeded by the lack of novel screening technologies that overcome the difficulties inherent in screens based on whole organism toxicity. The development and implementation of mechanism-based screens for new anthelmintics offers great promise for the revitalization of antiparasitic drug discovery. However, mechanism-based screens must be based on a thorough understanding of the proteins or processes that offer the best chance for selective chemotherapeutic intervention. Basic research on the characterization of nematode FMRFamide-related peptides (FaRPs) has revealed that these peptides are ubiquitously distributed in helminths. Chemical identification of a number of nematode FaRPs has been achieved, and these peptides have potent and profound effects on the nematode neuromuscular system. Physiological processes mediated by nematode FaRPs (and other helminth neuropeptides) offer potential targets for the discovery of novel anthelmintics.


International Journal for Parasitology | 2002

Structure–activity relationships of an inhibitory nematode FMRFamide-related peptide, SDPNFLRFamide (PF1), on Ascaris suum muscle

Jerry W. Bowman; Alan R. Friedman; David P. Thompson; Aaron G. Maule; Susan J. Alexander-Bowman; Timothy G. Geary

FMRFamide-related peptides are widespread among the Nematoda. Among them is a family of extended PNFLRFamide peptides encoded on the flp-1 peptide precursor gene in Caenorhabditis elegans. The most studied peptide from this series is SDPNFLRFamide (PF1). Each residue in this peptide was sequentially substituted with either alanine or the corresponding d-isomer of the native amino acid in order to define structure-function relationships in this peptide using an Ascaris suum muscle tension assay. In general, substitutions in the N-terminal tetrapeptide had only minor consequences for efficacy, while substitutions in the C-terminal tetrapeptide caused more dramatic changes. Such substitutions typically markedly diminished efficacy, but d-isomer substitution at either position 5 (Phe) or 6 (Leu) converted the inhibitory activity of the prototype into excitation. In addition, it has been evident that KPNFLRFamide and SDPNFLRFamide, though encoded on flp-1 and sharing a PNFLRFamide hexapeptide, act through different receptors. KPNFLRFamide directly gates a chloride channel in A. suum muscle cells, while SDPNFLRFamide acts through nitric oxide synthase to open K+ channels in the same tissue. The use of K+ channel blockers and nitric oxide synthase inhibitors in electrophysiological experiments employing A. suum muscle membranes allowed the unambiguous conclusion that the N-terminal lysine is absolutely required for activation of the chloride channel and excludes interaction with the SDPNFLRFamide receptor.


International Journal for Parasitology | 1996

Nematode FMRFamide-related peptide (FaRP)-systems: Occurrence, distribution and physiology

Aaron G. Maule; Timothy G. Geary; Nicola Marks; J.W. Bowman; Alan R. Friedman; David P. Thompson

The application of rational (mechanism-based) approaches to anthelmintic discovery requires information about target proteins which are pharmacologically distinguishable from their vertebrate homologs. In helminths, several such targets (e.g., beta-tubulin, ATP-generating enzymes, cholinergic receptors, CI- channels) have been characterized only after the discovery, through empirical screening, of compounds that interfere with their function. From the perspective of anthelmintic discovery, the utility of these targets is diminishing due to the emergence of drug-resistant strains of parasites. This has motivated the search for compounds with novel modes-of-action. Recent basic research in helminth physiology and biochemistry has identified several potential targets for rational anthelmintic discovery, including receptors for FMRFamide-related peptides (FaRPs). To date, over 20 different nematode FaRPs have been identified and these peptides, which are broadly distributed in helminths, have been localized to all of the major neuronal subtypes in nematodes. The FaRPs that have been examined have been found profoundly to affect somatic muscle function in gastrointestinal nematodes. In this respect, complex inhibitory and excitatory actions have been identified for a number of these peptides. Although the transduction pathways for any of these peptides remain to be elucidated, the available evidence indicates that nematode FaRPs have numerous mechanisms of action. The employment of nematode neuropeptide receptors in mechanism-based screens has immense potential in the identification of novel anthelmintics.


Archive | 1996

Synthetic Analogues of Growth Hormone Releasing Factor (GHRF) with Improved Pharmaceutical Properties

Teresa M. Kubiak; Alan R. Friedman; W. Michael Moseley

The protein hormone, somatotropin or growth hormone (GH), is essential for normal somatic growth. The biologic activity of GH is species specific. Currently, recombinant human GH is used for increasing growth in children with short stature, while recombinant bovine growth hormone is registered for enhancing lactation in cows. The secretion of GH from the anterior pituitary is controlled by two hypothalamic peptides, somatostatin (inhibitory) and growth hormone releasing factor (GHRF, stimulatory). GHRF offers a potential alternative to GH in applications where increased circulating concentrations of GH are desirable.


International Journal of Peptide and Protein Research | 2009

Degradation of growth hormone releasing factor analogs in neutral aqueous solution is related to deamidation of asparagine residues. Replacement of asparagine residues by serine stabilizes.

Alan R. Friedman; Avneet K. Ichhpurani; D. M. Brown; R. M. Hillman; L. F. Krabill; R. A. Martin; H. A. Zurcher-Neely; D. M. Guido


International Journal of Peptide and Protein Research | 2009

Effect of secondary structure on the rate of deamidation of several growth hormone releasing factor analogs

Cynthia L. Stevenson; Alan R. Friedman; Teresa M. Kubiak; Mary E. Donlan; Ronald T. Borchardt


Journal of Medicinal Chemistry | 1993

Position 2 and position 2/Ala15-substituted analogs of bovine growth hormone-releasing factor (bGRF) with enhanced metabolic stability and improved in vivo bioactivity

Teresa M. Kubiak; Alan R. Friedman; Roger A. Martin; Avneet K. Ichhpurani; Glenn R. Alaniz; William H. Claflin; Martha C. Goodwin; Diane L. Cleary; Colleen R. Kelly


Archive | 1995

Stabilized potent GRF analogs

Teresa M. Kubiak; Alan R. Friedman


International Journal of Peptide and Protein Research | 2009

Solution conformation of Leu27 hGRF(1-32)NH2 and its deamidation products by 2D NMR

Cynthia L. Stevenson; Mary E. Donlan; Alan R. Friedman; Ronald T. Borchardt

Collaboration


Dive into the Alan R. Friedman's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar

Aaron G. Maule

Queen's University Belfast

View shared research outputs
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar

Teresa Kubiak

University of Texas at Austin

View shared research outputs
Researchain Logo
Decentralizing Knowledge